The revenue increase was primarily driven by increased revenue in the company's biopharma services, clinical services, and discovery services divisions.
Test volume was up 5 percent, but the company's total revenue of $83.8 million was negatively affected by hurricanes in the US, company executives said.
Labcyte and the University of Helsinki's Institute for Molecular Medicine Finland have expanded their partnership to include multiple new applications.
The Irving, Texas-based company claims that three of Foundation Medicine's cancer molecular profiling tests infringe five of its US patents.
For the three months ended Sept. 30, the firm reported total revenues of $190.2 million, compared to $177.5 million in Q1 2017, beating the consensus Wall Street estimate.
Veracyte attributed its lower Afirma sales in part to slowing down the rollout of an updated version of the test that relies on RNA sequencing.
Researchers are now using the approach to allow genome-wide sequencing to monitor disease and to investigate treatment response and resistance without the need for tissue biopsy.
The approved Ventana ALK (D5F3) immunohistochemistry CDx is available for use on the Roche BenchMark XT or BenchMark Ultra IHC/ISH slide staining systems.
The genomic testing company's total revenues were down to $17.5 million in the quarter, although its genomic testing volume increased 14 percent.
The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software.
As of this week, the project had sequenced 39,500 genomes and returned reports for about 3,000 rare disease families and more than 600 cancer patients.
This is the first US Food and Drug Administration approval for a drug based solely on data from a basket study.
The researchers found that most advanced EGFR-mutant lung cancer patients harbored changes in an average of two to three other oncogenes.
The new funding comes from life sciences investment firm Perceptive Advisors. Home Care Assistance CEO Lily Sarafan has also joined Counsyl's board.
Researchers at Aarhus will use Natera's liquid biopsy assay to monitor colorectal cancer patients after surgery and chemotherapy.
Adaptive Biotechnologies will measure minimal residual disease in multiple myeloma patients as part of an Amgen-sponsored clinical trial.
The company believes its system, launched earlier this year, can outperform other microfluidic technologies, yielding samples with fewer white blood cells that allow better genomic analyses.
The company believes it can overcome its challenges, and highlighted strong continued interest from pharma despite a disappointing end to its Merck deal.
An analysis of new and available liver cancer genomes led to 10 mutational signatures and six structural rearrangement signatures in hepatocellular carcinoma.
The agency is excluding certain advanced diagnostic lab tests and molecular pathology tests from a billing regulation that created administrative headaches for many labs.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.